Correlation of the Rac1/RhoA pathway with ezrin expression in osteosarcoma

Applied Immunohistochemistry and Molecular Morphology

Volumn 22, Issue 3, 2014, Pages 162-170

  Chiappetta, Caterina ^a   Leopizzi, Martina ^a   Censi, Fabiana ^a   Puggioni, Chiara ^a   Petrozza, Vincenzo ^a   Rocca, Carlo D ^a   Di Cristofano, Claudio ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Ezrin; Osteosarcoma; Rac1; RhoA; Rhogtpase

Indexed keywords

EZRIN; RAC1 PROTEIN; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; SMALL INTERFERING RNA; CYTOSKELETON PROTEIN;

ARTICLE; CANCER GROWTH; CELL MOTILITY; CLINICAL FEATURE; COMPARATIVE STUDY; CONTROLLED STUDY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; OSTEOSARCOMA; OSTEOSARCOMA CELL LINE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; WESTERN BLOTTING; BONE TUMOR; CARCINOGENESIS; FOLLOW UP; GENETICS; IMMUNOLOGY; METABOLISM; METASTASIS; PROGNOSIS; SURVIVAL; TISSUE MICROARRAY; TUMOR CELL LINE;

BONE NEOPLASMS; CARCINOGENESIS; CELL LINE, TUMOR; CYTOSKELETAL PROTEINS; FOLLOW-UP STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; NEOPLASM METASTASIS; OSTEOSARCOMA; PROGNOSIS; RAC1 GTP-BINDING PROTEIN; RHOA GTP-BINDING PROTEIN; RNA, SMALL INTERFERING; SURVIVAL ANALYSIS; TISSUE ARRAY ANALYSIS;

EID: 84910129287     PISSN: 15412016     EISSN: 15334058     Source Type: Journal    
DOI: 10.1097/PDM.0000000000000033     Document Type: Article

References (51)

1. Raymond AK, Ayala AG, Knuutila S. Conventional osteosarcoma. In: Fletcher CDM, Unni KK, Mertens F, eds. World Health Organization Classification of Tumours Pathology and Genetics of Tumours of Soft Tissue and Bone. Lyon: IARC Press; 2002:264-270.
2. Damron TA, Ward WG, Stewart A. Osteosarcoma chondrosarcoma and Ewing's sarcoma: National Cancer Data Base report. Clin Orthop Relat Res. 2007;459:40-47.
3. Harris MB, Gieser P, Goorin AM, et al. Treatment of metastatic osteosarcoma at diagnosis: A Pediatric Oncology Group Study. J Clin Oncol. 1998;16:3641-3648.
4. PosthumaDeBoer J, Witlox MA, Kaspers GJ, et al. Molecular alterations as target for therapy in metastatic osteosarcoma: A review of literature. Clin Exp Metastasis. 2011;28:493-503.
5. Hattinger CM, Pasello M, Ferrari S, et al. Emerging drugs for high-grade osteosarcoma. Expert Opin Emerg Drugs. 2010;15: 615-634.
6. Lewis IJ, Nooij MA, Whelan J, et al. Improvement in histologic response but not survival in osteosarcoma patients treated with intensified chemotherapy: A randomized phase III trial of the European Osteosarcoma Intergroup. J Natl Cancer Inst. 2007; 99:112-128.
7. Bacci G, Briccoli A, Rocca M, et al. Neoadjuvant chemotherapy for osteosarcoma of the extremities with metastases at presentation: recent experience at the Rizzoli Institute in 57 patients treated with cisplatin, doxorubicin, and a high dose of methotrexate and ifosfamide. Ann Oncol. 2003;14:1126-1134.
8. Kager L, Zoubek A, Potschger U, et al. Primary metastatic osteosarcoma: presentation and outcome of patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols. J Clin Oncol. 2003;21:2011-2018.
9. Khanna C, Khan J, Nguyen P, et al. Metastasis-associated differences in gene expression in a murine model of osteosarcoma. Cancer Res. 2001;61:3750-3759.
10. Khanna C, Wan X, Bose S, et al. The membrane-cytoskeleton linker ezrin is necessary for osteosarcoma metastasis. Nat Med. 2004; 10:182-186.
11. Bretscher A, Edwards K, Fehon RG. ERM proteins and merlin: integrators at the cell cortex. Nat Rev Mol Cell Biol. 2002;3:586-599.
12. Mangeat P, Roy C, Martin M. ERM proteins in cell adhesion and membrane dynamics. Trends Cell Biol. 1999;9:187-192.
13. Hunter KW. Ezrin, a key component in tumor metastasis. Trends Mol Med. 2004;10:201-204.
14. Tsukita S, Yonemura S. ERM (ezrin/radixin/moesin) family: from cytoskeleton to signal transduction. Curr Opin Cell Biol. 1997;9: 70-75.
15. Granés F, Urena JM, Rocamora N, et al. Ezrin links syndecan-2 to the cytoskeleton. J Cell Sci. 2000;113:1267-1276.
16. Lozupone F, Lugini L, Matarrese P, et al. Identification and relevance of the CD95-binding domain in the N-terminal region of ezrin. J Biol Chem. 2004;279:9199-9207.
17. van Buul, JD, Mul FPJ, van der Schoot CE, et al. ICAM-3 activation modulates cell-cell contacts of human bone marrow endothelial cells. J Vasc Res. 2004;41:28-37.
18. Yang S, Guo X, Debnath G, et al. Protein 4.1R links E-cadherin/beta-catenin complex to the cytoskeleton through its direct interaction with beta-catenin and modulates adherens junction integrity. Biochim Biophys Acta. 2009;1788:1458-1465.
19. Morrison H, Sherman LS, Legg J, et al. The NF2 tumor suppressor gene product, merlin, mediates contact inhibition of growth through interactions with CD44. Genes Dev. 2001;15:968-980.
20. Weng WH, Ahlen J, Astrom K, et al. Prognostic impact of immunohistochemical expression of ezrin in highly malignant soft tissue sarcomas. Clin Cancer Res. 2005;11:6198-6204.
21. Yu Y, Khan J, Khanna C, et al. Expression profiling identifies the cytoskeletal organizer ezrin and the developmental homeoprotein Six-1 as key metastatic regulators. Nat Med. 2004;10:175-181.
22. Pang ST, Fang X, Valdman A, et al. Expression of ezrin in prostatic intraepithelial neoplasia. Urology. 2004;63:609-612.
23. Ilmonen S, Vaheri A, Asko-Seljavaara S, et al. Ezrin in primary cutaneous melanoma. Mod Pathol. 2005;18:503-510.
24. Ridley AJ. Rho family proteins: coordinating cell responses. Trends Cell Biol. 2001;11:471-477.
25. Jaffe AB, Hall A. Rho GTPases: biochemistry and biology. Annu Rev Cell Dev Biol. 2005;21:247-269.
26. Aspenstrom P, Ruusala A, Pacholsky D. Taking RhoGTPases to the next level: The cellular functions of atypical Rho GTPases. Exp Cell Res. 2007;313:3673-3679.
27. Vega FM, Ridley AJ. Rho GTPases in cancer cell biology. FEBS Lett. 2008;582:2093-2101.
28. Gómez del Pulgar T, Benitah SA, Valerón PF, et al. Rho GTPase expression in tumourigenesis: evidence for a significant link. Bioessays. 2005;6:602-613.
29. Takahashi K, Sasaki T, Mammoto A, et al. Direct interaction of the Rho GDP dissociation inhibitor with ezrin/radixin/moesin initiates the activation of the Rho small G protein. J Biol Chem. 1997; 272:23371-23375.
30. Martín-Villar E, Megías D, Castel S, et al. Podoplanin binds ERM proteins to activate RhoA and promote epithelial-mesenchymal transition. J Cell Sci. 2006;119:4541-4553.
31. Di Cristofano, C, Leopizzi M, Miraglia A, et al. Phosphorylated ezrin is located in the nucleus of the osteosarcoma cell. Mod Pathol. 2010;23:1012-1020.
32. Hsieh YS, Chu SC, Yang SF, et al. Silibinin suppresses human osteosarcoma MG-63 cell invasion by inhibiting the ERK-dependent c- Jun/AP-1 induction of MMP-2. Carcinogenesis. 2007;28:977-987.
33. Sahai E, Marshall CJ. RHO-GTPases and cancer. Nat Rev Cancer. 2002;2:133-142.
34. Hall A. Rho GTPases and the actin cytoskeleton. Science. 1998; 5350:509-514.
35. Kamai T, Arai K, Tsuji T, et al. Overexpression of RhoA mRNA is associated with advanced stage in testicular germ cell tumor. BJU Int. 2001;87:227-231.
36. Fritz G, Just I, Kaina B. Rho GTPases are overexpressed in human tumors. Int J Cancer. 1999;81:682-687.
37. Zondag GC, Evers EE, ten Klooster JP, et al. Oncogenic Ras downregulates Rac activity which leads to increased Rho activity and epithelial-mesenchymal transition. J Cell Biol. 2000;149:775-782.
38. Sahai E, Olson MF, Marshall CJ. Cross-talk between Ras and Rho signaling pathways in transformation favours proliferation and increased motility. EMBO J. 2001;20:755-766.
39. Hunter KW. Ezrin, a key component in tumor metastasis. Trends Mol Med. 2004;10:201-204.
40. Ota T, Maeda M, Suto S, et al. LyGDI functions in cancer metastasis by anchoring Rho proteins to the cell membrane. Mol Carcinog. 2004;39:206-220.
41. Ma L, Liu Y, Zhang X, et al. Relationship of RhoA signaling activity with ezrin expression and its significance in the prognosis for breast cancer patients. Chin Med J. 2013;126:24-247.
42. Yang H, Hinds PW. Phosphorylation of ezrin by cyclin-dependent kinase 5 induces the release of Rho GDP dissociation inhibitor to inhibit Rac1 activity in senescent cells. Cancer Res. 2006;66: 2708-2715.
43. Ferrari S, Zanella L, Alberghini M, et al. Prognostic significance of immunohistochemical expression of ezrin in nonmetastatic highgrade osteosarcoma. Pediatr Blood Cancer. 2008;50:752-756.
44. Li Q, Wu M, Wang H, et al. Ezrin silencing by small hairpin RNA reverses metastatic behaviors of human breast cancer cells. Cancer Lett. 2008;261:55-63.
45. Shen ZH, Chen XY, Chen J. Impact of up-regulating Ezrin expression by Epstein-Barr virus latent membrane protein 1 on metastasis ability of nasopharyngeal carcinoma cells. Ai Zheng. 2008;27:165-169.
46. Musia J, Sporny S, Nowicki A. Prognostic significance of Ecadherin and ezrin immunohistochemical expression in prostate cancer. Pol J Pathol. 2007;58:235-243.
47. McClatchey AI. Merlin and ERM proteins: unappreciated roles in cancer development? Nat Rev Cancer. 2003;3:877-883.
48. Elliott BE, Meens JA, SenGupta SK, et al. The membrane cytoskeletal crosslinker ezrin is required for metastasis of breast carcinoma cells. Breast Cancer Res. 2005;7:365-373.
49. Wang HJ, Zhu JS, Zhang Q, et al. RNAi-mediated silencing of ezrin gene reverses malignant behavior of human gastric cancer cell line SGC-7901. J Dig Dis. 2009;10:258-264.
50. Ling ZQ, Mukaisho K, Yamamoto H, et al. Initiation of malignancy by duodenal contents reflux and the role of ezrin in developing esophageal squamous cell carcinoma. Cancer Sci. 2010;101:624-630.
51. Fellenberg J, Bernd L, Delling G, et al. Prognostic significance of drug-regulated genes in high-grade osteosarcoma. Mod Pathol. 2007;20:1085-1094.